Monoclonal Antibodies Stocks List Ranked for 2024

Symbol	Grade	Name	% Change
ZYME	C	Zymeworks Inc.	4.82
ROIV	C	Roivant Sciences Ltd.	4.44
XOMA	C	XOMA Corporation	-0.23
DYAI	B	Dyadic International, Inc.	12.57
FBRX	B	Forte Biosciences, Inc.	1.50
IFRX	B	InflaRx N.V.	4.85
XNCR	B	Xencor, Inc.	3.42
TGTX	B	TG Therapeutics, Inc.	2.08
CDMO	A	Avid Bioservices, Inc.	0.04

Symbol	Grade	Name	Weight
CNCR	F	Loncar Cancer Immunotherapy ETF	6.77
IDNA	D	iShares Genomics Immunology and Healthcare ETF	6.18
KURE	D	KraneShares MSCI All China Health Care Index ETF	6.12
CANC	D	Tema Oncology ETF	5.78
IBBQ	D	Invesco Nasdaq Biotechnology ETF	5.24

Compare ETFs

Date	Stock	Title
Nov 21	ZYME	Jazz and Zymeworks announce FDA approval of cancer therapy Ziihera
Nov 21	ZYME	FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
Nov 21	TGTX	TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
Nov 20	FBRX	Crude Oil Moves Lower; Williams-Sonoma Shares Gain After Q3 Results
Nov 20	FBRX	Forte Biosciences announces oversubscribed $53 million private placement
Nov 20	FBRX	Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
Nov 19	IFRX	Is InflaRx N.V. (IFRX) the Best German Stock to Buy Now?
Nov 19	ROIV	Roivant Sciences' (NASDAQ:ROIV) Shareholders Should Assess Earnings With Caution
Nov 18	XNCR	Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade
Nov 17	CDMO	Avid Bioservices, Inc. (CDMO): A Bull Case Theory

Monoclonal Antibodies: Monoclonal antibodies (mAb or moAb) are antibodies that are made by identical immune cells that are all clones of a unique parent cell. Monoclonal antibodies can have monovalent affinity, in that they bind to the same epitope (the part of an antigen that is recognized by the antibody). In contrast, polyclonal antibodies bind to multiple epitopes and are usually made by several different plasma cell (antibody secreting immune cell) lineages. Bispecific monoclonal antibodies can also be engineered, by increasing the therapeutic targets of one single monoclonal antibody to two epitopes.